Management Compensation & Development Committee Charter

CELGENE CORPORATION
MANAGEMENT COMPENSATION AND DEVELOPMENT
COMMITTEE CHARTER
(amended and restated June 12, 2013)

The Management Compensation and Development Committee (the "Compensation Committee") is a standing committee appointed by the Board of Directors (the "Board") of Celgene Corporation (the "Corporation").

The Committee shall consist of three or more members of the Board, each of whom shall be a "non-employee director" as defined in Rule 16b-3 under the Securities Exchange Act of 1934, as amended, meet the independence requirements of NASDAQ Stock Market Listing Rule 5605 and be an "outside director" for purposes of Section 162(m) of the Internal Revenue Code, as amended.

The Board, based on nominations recommended by the Corporation's Nominating and Governance Committee, shall elect members of the Compensation Committee, and shall designate one member as Chair. The Board may appoint and remove Compensation Committee members in accordance with the Corporation's by-laws.

The primary purposes of the Compensation Committee are to: (i) assist the Board in the discharge of its responsibilities relating to compensation of the Chief Executive Officer (the "CEO") and other reporting officers (as defined in the same manner as "officer" in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended); (ii) produce annually the Compensation Committee Report To Stockholders on Executive Compensation for inclusion in the Corporation's proxy statement; (iii) ensure that the Corporation's compensation plans for the CEO and other reporting officers are competitive, support the Corporation's overall business strategy and align with the Corporation's compensation philosophy; (iv) review, evaluate and approve the CEO and other reporting officer compensation plans and performance; (v) review and discuss with management the compensation, discussion and analysis ("CD&A") to be included in the Corporation's proxy statement; and (vi) make recommendations to the Board concerning the compensation of non-employee members of the Board.

The Compensation Committee's duties and responsibilities also include the following:

  1. Review and approve on an annual basis the performance goals and objectives for the CEO and other reporting officers, and annually review and evaluate the performance of the CEO and other reporting officers against such previously established goals and objectives. Taking into consideration these performance evaluations, the Corporation's compensation philosophy, and a review of competitive compensation levels, the Compensation Committee will set the base salary, bonus, incentive and equity compensation levels for the CEO and other reporting officers;
  2. Select a peer group of companies against which to benchmark the Corporation's compensation policies and practices for the CEO and the other reporting officers;
  3. Regularly review and evaluate the compensation programs for Board and committee members, and as appropriate, recommend changes to the Board;
  4. Review the Corporation's short- and long-term incentive compensation and equity award programs and recommend to the Board changes to such programs or development of new programs;
  5. Review and approve the annual stock option pool under the Corporation's equity award programs;
  6. Review and approve contracts and amendments thereto relating to the compensation of the CEO and the other reporting officers, as appropriate;
  7. Review and approve the Corporation's annual corporate goals and the achievement of bonus, incentive and other payouts and awards for the CEO, other reporting officers, members of the Corporation's management committee and members of the Corporation's operating committee, as appropriate;
  8. Maintain written minutes of its meetings that will be kept with the minutes of committee meetings of the Corporation;
  9. Make regular reports on Compensation Committee activities to the Board;
  10. Review and re-assess, at least annually, the adequacy of this Charter and recommend any proposed changes to the Board for approval;
  11. Review and recommend to the Board compensation programs for non-employee directors, committee chairpersons and committee members;
  12. Administer the Corporation's equity award programs, except that the Compensation Committee may delegate to one or more officers the authority to make grants of share-based awards to eligible individuals other than directors, provided that the Compensation Committee shall have fixed the exercise price or a formula for determining the exercise price, the vesting schedule and any other provisions and parameters relating thereto as the Compensation Committee deems necessary or desirable;
  13. Review, at least annually, incentive compensation arrangements to confirm that such arrangements do not encourage unnecessary risk-taking and report the results of this review to the Board;
  14. Retain, at the Corporation's expense, and terminate any compensation consultant, counsel or other adviser to the Compensation Committee and approve the related fees and other retention terms and otherwise supervise the activities of such persons; and
  15. Select or receive advice from, any compensation consultant, legal counsel or other adviser to the Compensation Committee (other than in-house legal counsel), only after taking into consideration the following factors:1
    1. the provision of other services to the Corporation by the firm that employs the compensation consultant, counsel or other adviser;
    2. the amount of fees paid by the Corporation to the firm that employs the compensation consultant, counsel or other adviser, as a percentage of the firm's total revenue;
    3. the policies and procedures of the firm that employs the compensation consultant, counsel or other adviser that are designed to prevent conflicts of interest;
    4. any business or personal relationship between the compensation consultant, counsel or other adviser and a Compensation Committee member;
    5. any Corporation stock owned by the compensation consultant, counsel or other adviser; and
    6. any business or personal relationship between the compensation consultant, counsel or other adviser or the firm that employs such person and an executive officer of the Corporation.

The Compensation Committee will have the authority, to the extent it deems necessary or desirable, to retain or obtain the advice of one or more compensation consultants, legal counsel or other advisers. The Compensation Committee shall be directly responsible for the appointment, compensation and oversight of the work of any such compensation consultants, legal counsel and other advisers retained by the Compensation Committee. The Corporation shall provide for appropriate funding, as determined by the Compensation Committee, for payment of reasonable compensation to any compensation consultants, legal counsel or any other advisers retained by the Compensation Committee.

The Compensation Committee shall meet as often as its members deem necessary to perform the Compensation Committee's responsibilities. The Compensation Committee is governed by the same rules regarding meetings, action without meetings, notice, waiver of notice, and quorum and voting requirements as are applicable to the Board. In any deliberations or voting to determine the compensation of the CEO, the CEO must not be present.

1The Compensation Committee need not conduct an independence assessment prior to receiving advice from (i) in-house legal counsel or (ii) any consultant, counsel or other adviser if the role of such consultant, counsel or other adviser is limited to:

  • consulting on any broad-based plan that does not discriminate in favor of executive officers or directors and that is available generally to all salaried employees; or
  • providing information that either is not customized for a particular Corporation or that is customized based on parameters that are not developed by the adviser.

Committee Members

Chair Ernest Mario, Ph.D.
X
Ernest Mario, Ph.D.
Former Deputy Chairman and Chief Executive of Glaxo Holdings plc.

Ernest Mario, Ph.D . has served as one of Celgene's directors since August 2007 and is a member of the Nominating Committee since August 2007, the Executive Committee since June 2008 and Chairman of the Compensation Committee since August 2014. Dr. Mario is a former Deputy Chairman and Chief Executive of Glaxo Holdings plc and a former Chairman and Chief Executive Officer of ALZA Corporation. Dr. Mario also serves as a director of publicly-traded healthcare companies: Capnia, Inc. (chairman of the board), Boston Scientific Corporation (member of audit committee and chair of compensation committee), Chimerix Inc. (chairman of the board and member of the nominating and governance committee), Kindred Biosciences Inc. (chairman of the audit committee and member of the compensation committee), XenoPort Inc. (member of the nominating and governance committee) and Tonix Pharmaceuticals Holding Corp. (member of the compensation committee). He is Chairman of the American Foundation for Pharmaceutical Education and serves as an advisor to The Ernest Mario School of Pharmacy at Rutgers University. In 2007, Dr. Mario was awarded the Remington Medal by the American Pharmacists Association, pharmacy's highest honor. Dr. Mario brings to his service as a director his significant executive leadership experience, including his experience leading several pharmaceutical companies, as well as his membership on public company boards and foundations. He also has extensive experience in financial and operations management, risk oversight, and quality and business strategy.

Committee Member Michael D. Casey
X
Michael D. Casey
Former President and Chief Executive Officer of Matrix Pharmaceutical, Inc.

Michael D. Casey has served as one of our directors since August 2002, and has been our independent Lead Director since June 2007, the  Chairman of the Nominating Committee and a member of the Executive Committee since December 2006, and a member of the Management  Compensation and Development Committee (referred to as the Compensation Committee) since April 2006. Mr. Casey was a member of the  Audit Committee from August 2002 through December 2006. From September 1997 to February 2002, Mr. Casey served as the Chairman,  President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997, Mr. Casey was  Executive Vice President at Schein Pharmaceutical, Inc. In December 1996, he was appointed President of the retail and specialty products  division of Schein Pharmaceutical, Inc. From June 1993 to November 1995, he served as President and Chief Operating Officer of Genetic  Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey is also a director of  Abaxis Inc. Mr. Casey served as a director of Allos Therapeutics, Inc. through January 2010, AVI BioPharma (now Sarepta Therapeutics, Inc.)  through June 2010 and Durect Corporation through December 2013.  

Mr. Casey brings to his service as a director his significant experience and leadership as President, Chief Executive Officer and senior  officer of several national pharmaceutical companies. In addition to those listed above, he has previously served as a director of several other  pharmaceutical/biotech companies.

Committee Member James J. Loughlin
X
James J. Loughlin
Retired Partner KPMG, LLP

James J. Loughlin has served as one of our directors since January 2007, as Chairman of the Audit Committee since June 2008 and a member of the Compensation Committee since June 2008. Mr. Loughlin served as the National Director of the Pharmaceuticals Practice at KPMG LLP (KPMG), and a five-year term as member of the Board of Directors of KPMG. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees. Mr. Loughlin serves as a member of the Board of Directors and the Audit Committee of Edge Therapeutics, Inc., a privately-held biopharmaceutical company, and InspireMD, a publicly-traded medical device manufacturer.

Mr. Loughlin brings to his service as a director his valuable experiences as National Director of the Pharmaceuticals Practice at KPMG, his service as Chairman of the Pension and Investment Committee of the KPMG Board and his service on various other committees and foundations. In particular, through his professional association with KPMG, including a five-year term as member of the Board of Directors of KPMG, Mr. Loughlin brings to our Board of Directors an extensive background in accounting and financial reporting, qualifying him as an audit committee financial expert (as that term is defined in the regulations of the SEC).